Scientific Review Committee Meets on OncBioMune’s Phase 2 Prostate Cancer Clinical Trial
BATON ROUGE, La., March 22, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy …